# psoriasis - gemini-3.6-flash

- Benchmark system: E2seq + Agent RAG
- Repeat: 4
- Task type: DISEASE-STATE
- Tissue / sample source: lesional skin
- Comparison or endpoint: psoriatic lesional skin versus normal control skin
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Google Gemini / gemini-3.6-flash
- Message SHA-256: d1a33d3f606c81814c4fb94a6c63c8f1abebd3bde37d769e82eae4772d8ff873
- Response HTTP status: 200
- Prompt tokens: 40381
- Completion tokens: 19580
- Reasoning tokens: 8347
- Total tokens: 59961
- API requests reported: 2
- Elapsed seconds: 53.128
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1150.303
- Question handoff seconds: 1163.566
- Final benchmark system: E2seq; file rank 2/5; original repeat 4; model vendor: Google Gemini

---
Based on the user-provided differential expression statistical ledger (psoriatic lesional skin versus normal control skin) and integrated molecular annotations, here is the multidimensional transcriptomic interpretation.

---

### 1. Overall Biological Interpretation

The transcriptomic landscape of psoriatic lesional skin compared to normal control skin reflects a highly coordinated, multi-faceted disease state characterized by three dominant pathophysiological axes:
1. **Severe Alteration of Epidermal Differentiation & Cornified Envelope Dynamics:** Massive induction of structural epidermal proteins (small proline-rich proteins [`SPRR` family], late cornified envelope proteins [`LCE3A`, `LCE3D`], keratins [`KRT6A`], and gap junction proteins [`GJB2`, `GJB6`]) demonstrates the acanthosis, hyperkeratosis, and altered keratinocyte maturation characteristic of psoriatic plaques.
2. **Epithelial Antimicrobial & Alarmin Hyper-activation:** Profound upregulation of antimicrobial peptides (beta-defensins `DEFB4A`, `DEFB4B`, `DEFB103A/B`), S100 alarmins (`S100A7`, `S100A7A`, `S100A8`, `S100A12`), and endogenous peptidase inhibitors (`PI3`/elafin, `SERPINB3`, `SERPINB4`) highlights an activated innate mucosal/epithelial defense shield driven by cutaneous inflammation.
3. **Feed-Forward Interleukin & Chemokine Amplification Loops:** Robust activation of the IL-36 axis (`IL36A`, `IL36G`, `IL36RN`) and IL-20 cytokine family (`IL19`, `IL20`, `IL26`), alongside leukocyte chemoattractants (`CXCL13`, `CXCR2`), underscores an ongoing inflammatory dialog between damaged keratinocytes and infiltrating immune cells.

Conversely, down-regulated transcriptomic signals highlight a suppression of physiological epidermal growth factor homeostasis (e.g., marked reduction of betacellulin `BTC` [log2FC = -4.299]) and xenobiotic/lipid metabolizing pathways (`CYP2W1`, `UGT3A2`), indicating a loss of baseline tissue metabolic maintenance.

---

### 2. Core Biological Programs

```
                  +-------------------------------------------------------+
                  |         PSORIATIC LESIONAL SKIN TRANSCRIPTOME         |
                  +-------------------------------------------------------+
                                              |
        +------------------+------------------+------------------+------------------+
        |                  |                  |                  |                  |
        v                  v                  v                  v                  v
+---------------+  +---------------+  +---------------+  +---------------+  +---------------+
|   PROGRAM 1   |  |   PROGRAM 2   |  |   PROGRAM 3   |  |   PROGRAM 4   |  |   PROGRAM 5   |
|   Epidermal   |  |  IL-36/IL-17  |  | Antimicrobial |  |   Leukocyte   |  | Homeostatic & |
|Cornification &|  |  Cytokine Axis|  |  & Innate     |  | Retargeting & |  |  Metabolic    |
| Differentiation| | Amplification |  | Host Defense  |  | Immune Influx |  | Suppression   |
+---------------+  +---------------+  +---------------+  +---------------+  +---------------+
```

#### Program 1: Epidermal Cornification & Altered Differentiation Structural Program
* **Direction:** Upregulated in lesional skin
* **Major Supporting Genes:** `LCE3A` (log2FC=8.298), `SPRR2A` (log2FC=7.312), `SPRR3` (log2FC=7.180), `SERPINB3` (log2FC=6.742), `SPRR2B` (log2FC=6.380), `LCE3D` (log2FC=5.314), `KRT6A` (log2FC=4.303), `GJB2` (log2FC=4.419), `PI3` (log2FC=9.240).
* **Standardized Pathway:** Reactome: *Formation of the cornified envelope* (R-HSA-6809371); GO: *Epidermis Development* (GO:0008544).
* **Biological Rationale:** The co-induction of `SPRR` and `LCE` family envelope precursors together with cross-linking peptidase inhibitors (`PI3`, `SERPINB3/4`) represents the structural remodeling of the stratum corneum in response to inflammatory hyperproliferation.
* **Evidence Strength & Limitations:** Strong direct statistical signal (FDR < 1e-64 across genes). *Limitation:* Whole-skin bulk RNA sequencing cannot decouple intracellular differentiation programming from tissue composition shifts (e.g., increased proportion of suprabasal keratinocytes relative to basal cells).

#### Program 2: IL-36 / IL-17 Epithelial Cytokine Amplification Axis
* **Direction:** Upregulated in lesional skin
* **Major Supporting Genes:** `IL36A` (log2FC=11.374), `IL19` (log2FC=7.580), `IL36G` (log2FC=5.684), `IL20` (log2FC=5.667), `IL26` (log2FC=4.361), `IL36RN` (log2FC=3.005), `TNIP3` (log2FC=7.279), `ZC3H12A` (log2FC=3.848).
* **Standardized Pathway:** Reactome: *Interleukin-36 pathway* (R-HSA-9014826); KEGG: *IL-17 signaling pathway*.
* **Biological Rationale:** Epidermal keratinocytes produce `IL36A` and `IL36G` upon IL-17/TNF stimulation, which act autocrinely to induce downstream secondary cytokines (`IL19`, `IL20`). Concomitant elevation of endogenous negative regulators (`IL36RN`, `TNIP3`, `ZC3H12A`/MCPIP1) indicates a sustained feed-forward inflammatory circuit attempting counter-regulation.
* **Evidence Strength & Limitations:** Extremely high effect sizes (e.g., `IL36A` log2FC=11.37). *Limitation:* Transcript levels of cytokines do not measure extracellular protein processing, cleavage activation, or receptor binding stoichiometry.

#### Program 3: Antimicrobial Humoral Defense & Alarmin Production
* **Direction:** Upregulated in lesional skin
* **Major Supporting Genes:** `DEFB4A` (log2FC=11.183), `DEFB4B` (log2FC=11.031), `S100A7A` (log2FC=9.833), `S100A12` (log2FC=8.329), `S100A8` (log2FC=7.729), `S100A7` (log2FC=7.095), `DEFB103A` (log2FC=5.758), `DEFB103B` (log2FC=5.751).
* **Standardized Pathway:** GO: *Antimicrobial Humoral Response* (GO:0019730); KEGG: *Staphylococcus aureus infection*.
* **Biological Rationale:** Beta-defensins and S100 proteins serve dual roles as direct antimicrobial effectors against bacterial pathogens and as potent alarmins that activate innate immune receptors (TLR4/RAGE).
* **Evidence Strength & Limitations:** Highly consistent multi-gene family induction with fold changes > 5.0 log2FC. *Limitation:* Cannot distinguish epithelial keratinocyte-derived alarmins from infiltrating myeloid/neutrophilic cell line contributions.

#### Program 4: Leukocyte Chemotaxis & Immune Cell Retargeting
* **Direction:** Upregulated in lesional skin
* **Major Supporting Genes:** `CXCL13` (log2FC=5.893), `GPR15LG` (log2FC=5.516), `CD274`/PD-L1 (log2FC=3.440), `PRKCQ` (log2FC=2.881), `CXCR2` (log2FC=2.701), `ADAP2` (log2FC=2.089).
* **Standardized Pathway:** KEGG: *Cytokine-cytokine receptor interaction*; GO: *Response To Lipopolysaccharide* (GO:0032496).
* **Biological Rationale:** Elevation of B-cell/lymphoid chemoattractant `CXCL13`, neutrophil chemokine receptor `CXCR2`, and immune checkpoint ligand `CD274` indicates active recruitment and immunomodulation of infiltrating immune cells within the lesional dermis/epidermis.
* **Evidence Strength & Limitations:** Direct input dataset significance (FDR < 1e-62). *Limitation:* Reflects composite tissue signals of infiltrating cells rather than isolated resident skin cell functional states.

#### Program 5: Homeostatic EGFR Signaling Disruption & Cutaneous Metabolic Remodeling
* **Direction:** Mixed / Predominantly Downregulated homeostatic markers, Upregulated inflammatory metabolic enzymes
* **Major Supporting Genes:** `BTC` (log2FC=-4.299), `LOC107984452` (log2FC=-6.249), `CYP2W1` (log2FC=-4.704), `UGT3A2` (log2FC=-4.591), `AKR1B10` (log2FC=6.265), `PLA2G4D` (log2FC=4.615), `KYNU` (log2FC=4.416).
* **Standardized Pathway:** Reactome: *Phase II conjugation of compounds*; Reactome: *Metabolism of lipids*.
* **Biological Rationale:** Downregulation of EGF family ligand betacellulin (`BTC`) and phase I/II detoxification enzymes (`CYP2W1`, `UGT3A2`) signals a breakdown of normal epidermal basal stem cell proliferation and xenobiotic clearance, shifting toward inflammatory lipid mediation (`PLA2G4D`) and tryptophan catabolism (`KYNU`).
* **Evidence Strength & Limitations:** Clear directional divergence in the input ledger (downregulated genes log2FC < -4.0). *Limitation:* Functional enzymatic turnover and metabolic flux cannot be directly quantified from transcript abundance alone.

---

### 3. Key Genes and Interaction Modules

| Candidate Gene / Module | Direction in Dataset | Role in Core Programs | Proposed Relationship Type | Relationship Description |
| :--- | :--- | :--- | :--- | :--- |
| **`IL36A` & `IL36G`** | Upregulated (`IL36A`: +11.37, `IL36G`: +5.68) | Program 2 (IL-36/17 Axis) | **Pathway Co-membership & Regulatory Interaction** | Both act through the IL1RL2/IL1RAP receptor complex (STRING record) to induce upstream pro-inflammatory NF-kB cascades in keratinocytes. |
| **`DEFB4A` & `DEFB4B`** | Upregulated (`DEFB4A`: +11.18, `DEFB4B`: +11.03) | Program 3 (Antimicrobial Host Defense) | **Co-expression & Pathway Co-membership** | Genomic duplicate loci encoding Human Beta-Defensin 2; co-expressed under IL-17/IL-22 regulation and share CCR6 binding activity (STRING network). |
| **`S100A7A`, `S100A12`, `S100A8`** | Upregulated (`S100A7A`: +9.83, `S100A12`: +8.33, `S100A8`: +7.73) | Program 3 (Antimicrobial Defense) | **Direct Physical Interaction & Co-expression** | S100 proteins form homodimers/heterodimers (e.g., S100A8/A9 complexes) and physically interact with fatty acid binding proteins (STRING network). |
| **`PI3` & `SERPINB3` / `SERPINB4`** | Upregulated (`PI3`: +9.24, `SERPINB4`: +9.12, `SERPINB3`: +6.74) | Program 1 (Epidermal Differentiation) | **Pathway Co-membership & Co-expression** | Endogenous serine protease inhibitors cross-linked into the cornified envelope to protect against neutrophil-derived elastase/cathepsin tissue destruction. |
| **`SPRR2A` / `SPRR2B` / `LCE3A`** | Upregulated (`SPRR2A`: +7.31, `SPRR2B`: +6.38, `LCE3A`: +8.30) | Program 1 (Epidermal Differentiation) | **Pathway Co-membership** | Substrates transglutaminase-crosslinked during cornification (Reactome: *Formation of the cornified envelope*). |
| **`IL19` & `IL20`** | Upregulated (`IL19`: +7.58, `IL20`: +5.67) | Program 2 (IL-36/17 Axis) | **Pathway Co-membership & Regulatory Interaction** | IL-20 family cytokines downstream of IL-17 signaling that signal via IL-20R complexes to drive keratinocyte acanthosis. |
| **`BTC` (Betacellulin)** | Downregulated (`BTC`: -4.30) | Program 5 (Growth Factor & Homeostasis) | **Indirect / Putative Regulatory Relationship** | Loss of baseline EGFR ligand betacellulin correlates inversely with hyperproliferative inflammatory cytokine activation. |
| **`AKR1B10` & `KYNU`** | Upregulated (`AKR1B10`: +6.27, `KYNU`: +4.42) | Program 5 (Metabolic Remodeling) | **Pathway Co-membership** | Enzyamatic components driving inflammatory aldehyde detoxification (`AKR1B10`) and kynurenine pathway tryptophan metabolism (`KYNU`). |

---

### 4. Validation Priorities

#### Priority 1: Mechanistic Hypothesis — Feed-forward auto-amplification loop of epithelial IL-36 cytokines in keratinocytes
* **Classification:** Mechanistic hypothesis
* **Why Prioritized:** `IL36A` (+11.37) and `IL19` (+7.58) are among the highest fold-change DEGs in the dataset, pointing to an primary epithelial signaling engine.
* **Current Dataset Evidence:** Robust co-upregulation of `IL36A`, `IL36G`, `IL19`, `IL20`, alongside counter-regulatory `IL36RN` and `TNIP3`.
* **External Evidence:** Reactome annotations confirm shared IL1RAP receptor usage; however, *external statistical validation was not performed on an independent cohort in this analysis framework*.
* **Next Validation Step:** 3D organotypic human skin models with CRISPR knockouts of `IL36A` or `IL1RL2` stimulated with IL-17A to determine directional hierarchy.
* **Evidence Status:** **Supported hypothesis**

#### Priority 2: Therapeutic Target — Neutralization of the S100 Alarmin / Elafin (`PI3`) Axis
* **Classification:** Therapeutic target
* **Why Prioritized:** `S100A7A` (+9.83), `S100A12` (+8.33), and `PI3` (+9.24) demonstrate massive upregulation and extracellular secretion potential.
* **Current Dataset Evidence:** High statistically significant induction across multiple alarmin and inhibitor genes (FDR < 1e-65).
* **External Evidence:** OpenTargets and QuickGO associate S100 proteins with RAGE/TLR4 activation. *Note:* The existence of targeting molecules or database records does not prove therapeutic efficacy in psoriasis.
* **Next Validation Step:** Preclinical evaluation of S100A12- or PI3-neutralizing monoclonal antibodies in humanized mouse models of psoriasiform dermatitis.
* **Evidence Status:** **Exploratory hypothesis**

#### Priority 3: Biomarker — A 3-Gene Skin Biomarker Panel (`LCE3A` / `DEFB4A` / `S100A12`) for Lesional Severity
* **Classification:** Biomarker
* **Why Prioritized:** High effect sizes (> 8.0 log2FC) combined with extreme statistical significance (P < 1e-66) across differentiation, defense, and alarmin pathways.
* **Current Dataset Evidence:** `DEFB4A` (log2FC=11.183), `LCE3A` (log2FC=8.298), `S100A12` (log2FC=8.329).
* **External Evidence:** Literature (PubMed 40560938) links defensin/S100 levels to WGCNA disease activity modules in psoriasis.
* **Next Validation Step:** RT-qPCR and spatial transcriptomic validation in non-invasive tape strips from an independent longitudinal patient cohort before and after anti-IL-17/IL-23 therapy.
* **Evidence Status:** **Supported hypothesis**

#### Priority 4: Confounding / Composition Check — Single-Cell Deconvolution of Keratinocyte vs. Neutrophil Signatures
* **Classification:** Confounding or composition check
* **Why Prioritized:** High abundance of neutrophil-associated markers (`S100A8`, `S100A12`, `CXCR2`) occurs alongside epidermal structural markers (`SPRR2A`, `LCE3A`).
* **Current Dataset Evidence:** Concomitant upregulation of epithelial cell envelope transcripts and granulocyte chemoattractants/markers.
* **External Evidence:** Psoriatic histology is defined by neutrophilic infiltration (Munro's microabscesses). Bulk sequencing blends cell-intrinsic changes with cell-abundance changes.
* **Next Validation Step:** Single-cell RNA sequencing (scRNA-seq) or multiplexed fluorescence in situ hybridization (FISH) on lesional vs. non-lesional skin biopsies to decouple cell-type abundance shifts from per-cell differential expression.
* **Evidence Status:** **Established evidence** (Cell composition shift in bulk lesional tissue is a known anatomical feature).

#### Priority 5: Interaction / Network Hypothesis — Downregulation of Betacellulin (`BTC`) as a Driver of Keratinocyte Differentiation Arrest
* **Classification:** Interaction / network hypothesis
* **Why Prioritized:** `BTC` is one of the strongest downregulated genes (log2FC = -4.299), showing an inverse expression pattern to hyperproliferative markers.
* **Current Dataset Evidence:** Inverse correlation between downregulated `BTC` and upregulated `SPRR`/`LCE` differentiation modules.
* **External Evidence:** EGFR ligands regulate basal epidermal stem cell self-renewal versus terminal differentiation balance.
* **Next Validation Step:** Exogenous recombinant BTC treatment of primary human keratinocytes in the presence of IL-17/IL-36 to test if BTC restores homeostatic differentiation.
* **Evidence Status:** **Exploratory hypothesis**

---

### 5. Evidence Grounding

To maintain rigorous scientific evaluation, the supporting evidence types are explicitly categorized below:

```
+-----------------------------------------------------------------------------------+
|                               EVIDENCE CATEGORIZATION                             |
+-----------------------------------------------------------------------------------+
| 1. DIRECT INPUT STATISTICAL EVIDENCE                                             |
|    - Authoritative source for all 100 DEGs (e.g., VNN3P P=1.35e-150, IL36A P=2.54e-102|
|    - Establishes log2FC magnitude, direction (90 up / 10 down), and FDR thresholds.  |
|                                                                                   |
| 2. EXTERNAL STATISTICAL VALIDATION                                                |
|    - NOT AVAILABLE: External statistical validation was not performed on an      |
|      independent cohort in this analysis framework.                               |
|                                                                                   |
| 3. PATHWAY & ONTOLOGY ANNOTATION EVIDENCE                                         |
|    - Standardized Reactome (R-HSA-6809371, R-HSA-9014826) and QuickGO annotations  |
|      provide biological context for cornified envelope and cytokine signaling.     |
|                                                                                   |
| 4. PROTEIN INTERACTION & REGULATORY EVIDENCE                                      |
|    - STRING network records provide curated physical/functional associations      |
|      (e.g., SPRR2-LCE cross-linking, IL36A-IL1RAP receptor co-membership).         |
|                                                                                   |
| 5. THERAPEUTIC & LITERATURE EVIDENCE                                              |
|    - ChEMBL/OpenTargets records for CD274 and CXCR2 confirm druggability, while   |
|      literature (PMID 40560938) provides disease-association background.           |
+-----------------------------------------------------------------------------------+
```

* **Source Overlap & Independence Warning:** Ontology terms (QuickGO, Reactome) and PPI networks (STRING) frequently draw from overlapping primary literature sources and computational predictions. They represent qualitative background context rather than independent statistical replications of this cohort.

---

### 6. Limitations and Alternative Explanations

1. **Confounding by Tissue Cell-Composition Shifts:** Bulk skin tissue RNA sequencing averages transcript levels across keratinocytes, fibroblasts, endothelial cells, and infiltrating immune populations (neutrophils, T cells, dendritic cells). High fold changes in myeloid markers (`S100A12`, `CXCR2`, `S100A8`) primarily reflect the influx of inflammatory cells into lesional tissue rather than keratinocyte-intrinsic transcriptional upregulation alone.
2. **Absence of Independent External Cohort Replication:** External statistical validation was not performed on an independent cohort in this analysis. While internal statistical significance is high (FDR < 1e-60), generalizability to broader patient populations, diverse clinical subtypes (e.g., guttate vs. plaque psoriasis), or post-treatment settings requires independent cohort validation.
3. **Broad / Non-Specific Inflammatory Amplification Signatures:** Top-ranking DEGs such as `DEFB4A`, `PI3`, `S100A7`, and `CXCL13` are general acute-phase innate response markers induced by NF-kB/IL-17 signaling across multiple dermatological conditions (e.g., wound healing, hidradenitis suppurativa, atopic dermatitis). These signatures are not exclusive to psoriasis.
4. **Association vs. Causation Ambiguity:** Massive upregulation of cytokines (`IL36A`, `IL19`) and envelope structural proteins (`SPRR2A`, `LCE3A`) confirms a robust disease-associated transcriptomic state but cannot differentiate primary upstream drivers from secondary, reactive epidermal responses.
5. **Uncharacterized Loci and Non-Coding RNAs:** Strongly downregulated genes such as `LOC107984452` (log2FC = -6.249) and `WAKMAR1` (log2FC = -5.628), as well as upregulated lncRNAs (`LINC01206`, `LINC03232`), lack detailed functional annotation in standard biological databases, limiting definitive mechanistic interpretations.

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=48, external claims checked=0, external mismatches=0, status=passed.

Answer model API: Google Gemini / gemini-3.6-flash

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 91/100 selected items (records returned); cbioportal 91/100 selected items (records returned); chembl 11/100 selected items (partially returned; some queries failed); civic 4/100 selected items (records returned); clinicaltrials 40/100 selected items (records returned); clinvar 90/100 selected items (records returned); ensembl 44/100 selected items (partially returned; some queries failed); europepmc 848 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 83/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 76/100 selected items (records returned); humanbase 100/100 selected items (records returned); intact 79/100 selected items (records returned); mygene 100/100 selected items (records returned); omnipath 36/100 selected items (records returned); opentargets 90/100 selected items (records returned); pubmed 669 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 80/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 2/100 selected items (records returned); hmdb 25/100 selected items (records returned); string 78/100 selected items (records returned); trrust 17/100 selected items (records returned)
